Kurapa kweTIL (GT101)

GT101 imushonga wemasero emunhu wakagadzirwa neTIL yakawedzerwa uye yakavandudzwa kubva mubundu remurwere. Mushonga uyu unoitwa nekutora matishu ebundu kubva kuvarwere uye kubvisa TIL. TIL inobviswa ichawedzerwa uchishandisa chikuva chekugadzira cheGrit Bio cheStemTexp® uye ichadzorerwa kuvarwere kurwisa bundu.

Pagore ra2024Musangano Wegore Negore weAmerican Society of Clinical Oncology (ASCO),data rakataurwa pavarwere gumi nevana vane bundu rakasimba vaitora chikamu muchidzidzo cheGT101. Kuedzwa kwacho kwakagadzirwa nechinangwa chekutanga chekuongorora DLT uye kuratidza kuchengetedzeka kweGT101 muvarwere vane bundu rakasimba zvakayerwa nehuwandu hwezviitiko zvisina kunaka zveGiredhi ≥ 3 zvekurapa (TEAEs). Zvikamu zvechipiri zvaive zvekuongorora mashandiro azvo zvinosanganisira chiyero chemhinduro yose (ORR), chiyero chekutonga chirwere (DCR), kupona kusina progression (PFS), nguva yekupindura (DOR), uye kupona kwese (OS) zvichienderana neRECIST v1.1.

Mhedzisiro: Kubva musi wa10 Mbudzi, 2023, boka revanhu gumi nevana rakarapwa vaine makore anosvika 46.9 uye vari pakati nepakati pemitsetse miviri nehafu yemishonga yekare. Mushure mekurapwa kwakajairika kweFC-based lymphodepletion, varwere vakaiswa GT101 pamishonga ≥ 5×109 masero nepakati pemushonga we3.7×1010 masero, zvichiteverwa nekurapwa kweIL-2 nemushonga wepamusoro. Mazhinji eAEs eGiredhi ≥ 3 akaonekwa aive nehukama neFC conditioning regimen uye IL-2, kusanganisira kudzikira kwehuwandu hwelymphocyte, kudzikira kwehuwandu hwemasero machena eropa, kudzikira kwehuwandu hwema neutrophil, anemia, pyrexia uye kudzikira kwehuwandu hweplatelet. Mazhinji eAE aya akapora mukati memazuva gumi nemana, nepo mamwe mashoma akaderedzwa kusvika ku≤ Giredhi 2 mukati memavhiki mana. Pakati pevarwere gumi nemana vakanyoresa pazviratidzo zvakasiyana-siyana (kenza yemasero madiki-mapapu, melanoma, kenza yemuromo wechibereko), ORR yaive 35.7%. Zvikuru, 4 pts (28.6%) vaiva nemhinduro yakasimbiswa (PR), 1 pt (7.1%) vakawana mhinduro yakazara (CR), uye 8 pts (57.1%) vaiva nechirwere chakagadzikana (SD) semhinduro yavo yakanakisisa. 1 pt yaiva nekufambira mberi kwechirwere chisina kusimbiswa (PD). Zvinonyanya kukosha kuti, pakati pe11/14 varwere vane kenza yemumuromo wechibereko, ORR yaiva 45.5% (5/11) ne4 pts (36.4%) vakawana PR uye 1 pt (9.1%) vakawana CR. Kudzora chirwere kwakaonekwa mu10/11 pts (90.9%), uye avhareji yePFS yaive mwedzi 4.2 yeboka iri. Murwere weCR akaongororwa kwenguva refu uye nguva yeCR nePFS (inofungidzirwa naKaplan-Meier) yaive mavhiki makumi maviri nemana nemavhiki makumi matatu nematanhatu, zvichiteerana. Mushure mekuiswa kweGT101, masero eT akawedzera zvakanyanya muropa revarwere vese vane avhareji yeTmax mazuva 6.83 uye avhareji mazuva 15.9.

Mhedziso: Muchidzidzo cheGT101 Phase 1, hapana SAEs neDLT zvine chekuita nekurapwa zvakaonekwa. Muvarwere vane bundu rakasimba rakamborapwa kare kana kuti rakapararira, GT101 yakaratidza kuchengetedzeka kunogoneka pasi pechirongwa chekurapa che lymphodepletion uye IL-2 yakawanda uye chimiro chakanaka chekiriniki, kunyanya mukenza yemumuromo, neORR inokurudzira uye nguva refu yekupindura.

Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.

Nhamba yefoni: 4008803716

Email：myimmnet@163.com

Mareferensi

1.https://www.grit-bio.com/newsinfo/4620292.html

2. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2548